• Policy
• MOHW “reasonably decide on using A9 countries as reference"
• by Kim, Jung-Ju Dec 5, 2022 05:53am

• Policy
• The safety & efficacy evaluation of Jemperili was terminated
• by Lee, Hye-Kyung Dec 5, 2022 05:53am

• Policy
• Domestic new drug No. 36 Envlo has been approved
• by Lee, Hye-Kyung Dec 5, 2022 05:53am

• Policy
• Roche’s Lunsumio receives 1st GIFT designation in Korea
• by Lee, Hye-Kyung Dec 1, 2022 05:46am

• Policy
• The price of Donepezil 5mg fell below 500 won
• by Lee, Tak-Sun Dec 1, 2022 05:46am

• Policy
• Pediatric drugs eligible for PE exemptions from January
• by Kim, Jung-Ju Dec 1, 2022 05:46am

• Policy
• First Forxiga follow-on Dapapro listed at KRW 684
• by Lee, Tak-Sun Nov 29, 2022 05:54am

• Policy
• Avastin biosimilar will be reimbursed starting next month
• by Lee, Tak-Sun Nov 29, 2022 05:53am

• Policy
• Actilyse's price to rise 15% from next month
• by Kim, Jung-Ju Nov 28, 2022 05:50am

• Policy
• Crysvita, referred to the welfare committee
• by Lee, Jeong-Hwan Nov 28, 2022 05:50am